30 closest matches · ranked by relevance
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Severe Hepatic Impairment · Healthy
Primary: Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax) — 347.6; 280.3 ng/mL
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 40.0; 75.0; 50.0; 75.0 Percentage of participants
Healthy Men · Male Contraception · Healthy Women
Primary: Changes From Baseline (Cavg) for Serum Testosterone Levels in Females After Secondary Exposure to Nestorone + Testosterone Combination Gel — 22.84; 27.12; 29.12; 62.06…
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Healthy
Primary: The Mean (SD) Amount of [14C] Recovered in Urine, as a Percent of the Total [14C] Dose Administered — 25.2 percentage of dose
Acute Coronary Syndrome
Primary: Adverse Events of LC23-1306
Healthy
Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR
Aging · Insulin Resistance
Primary: Insulin Sensitivity — -0.16; 2.62; -0.50; 1.83 micro International Units/mL — p=0.023
Fluid Loss · Blood Loss
Primary: Impact of Subject Positioning on Percent Change of Heart Rate (HR) After Minor Blood Loss (e.g., 500mL) — 10.7; 14.7 percent change
Epilepsy
Primary: Cmax (BIA 2-005) — 10973; 11044; 11022 ng/mL
Short Bowel Syndrome · Parenteral Nutrition Associated Liver Disease
Primary: Number of Participants With AEs and SAEs Following Administration of NST 6179 — 4; 2; 2; 2 Participants
Pharmacodynamics · Healthy Subjects
Primary: Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. — -0.545…
Malaria
Primary: Cmax: Peak Plasma Concentration — 277; 373.4444 ng/mL
Hair Removal
Primary: Percent of Participants Correctly Determining Eligibility for Use of the Device (Responders) — 94 percentage of participants
Clexane is Administered to Healthy Volunteers
Primary: Anti-FXa Cmax — 0.999; 0.926 IU/mL
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06821497 — 3302; 3375; 3479; 11220 ng*hr/mL
Erythema · Edema
Primary: Number of Subjects With Observed Local Erythema Based on 5 Point Scale — 0 Participants
Autonomic Nervous System Imbalance · Hypothalamic Pituitary Adrenal Axis Suppression
Primary: Change From Baseline to Post Intervention High Frequency (HF) and Low Frequency Divided by High Frequency (LF/HF) Power Amplitude — 0.1796; 0.1507; -0.3872; 0.3731…
Skin Diseases
Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids
Pharmacokinetics · Tolerability
Primary: Pharmacokinetics — 11.0 ng/dL
This is a Phase I Study Conducted in Healthy Volunteers
Primary: Co-primary PK Endpoint Cmax: Maximum Serum Concentration — 12761.4; 12259.8 ng/mL
Healthy
Primary: Percentage of Participants With Treatment-emergent Drug-related Adverse Events (AEs) — 4.5; 0; 22.2; 0 percentage of participants
Healthy Volunteers
Primary: Nicotine Cmax — 13.00; 12.97; 6.00; 6.87 ng/mL
Healthy
Primary: After the First Dose: Area Under the Concentration-time Curve of BI 1467335 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) of BI 1467335 (After…
Erythema · Edema
Primary: Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale — 0 Participants